Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 15/20 | 0.75 |
| ▸ | MEN1 | O00255 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.56 |
| ▸ | MAX | P61244 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17934468 | 0.91 | MYC (0.76) | MYCMEN1KMT2AMAXPOLB | |
| SCHEMBL17934015 | 0.90 | MYC (0.71) | MYCMEN1KMT2AMAXPOLB | |
| SCHEMBL17934017 | 0.89 | MYC (0.72) | MYCMEN1KMT2AMAXPOLB | |
| SCHEMBL26266093 | 0.88 | MYC (0.75) | MYCMEN1KMT2AMAXPOLB | |
| SCHEMBL17927384 | 0.86 | MYC (0.82) | MYCMEN1KMT2AMAXPOLB | |
| SCHEMBL17927359 | 0.85 | MYC (1.00) | MYCMEN1KMT2AMAXPOLB | |
| SCHEMBL17927410 | 0.84 | MYC (0.73) | MYCMEN1KMT2AMAXPOLB | |
| SCHEMBL17927401 | 0.78 | MYC (0.69) | MYCMEN1KMT2AMAXPOLB | |
| SCHEMBL17934532 | 0.78 | MYC (0.68) | MYCMEN1KMT2AMAXPOLB | |
| SCHEMBL17927299 | 0.77 | MYC (0.70) | MYCMEN1KMT2AMAXPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| WO-2016115360-A1 | C-MYC LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2016-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | XIAP, CUL4A, CUL1 | MYC 226/4885MEN1 1062/4885KMT2A 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.